Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 451 - 500 out of 46,052

Document Document Title
WO/2014/029924
The present invention relates to novel nutritional and nutraceutical therapeutic uses of lactoferrin in psychiatric or non-degenerative neurological diseases.  
WO/2014/031584
The invention relates to compounds of Formula I, wherein R1, R2, and R3 are defined in the specification, useful for the synthesis of novel conjugates and immunogens derived from aripiprazole. The invention also relates to conjugates of ...  
WO/2014/030716
Provided is a pyrazolopyrimidine compound represented by formula (I) having an HIF-PHD inhibitory effect, or a pharmaceutically acceptable salt thereof. [In the formula, AA indicates an optionally substituted 7-hydroxypyrazolo[4,3-d]pyri...  
WO/2014/030170
The present invention relates to novel acrylamide compounds of formula (I), and their pharmaceutically acceptable salts and process of their preparation. (The chemical formula should be inserted here.) The compounds of formula (I) are us...  
WO/2014/031883
There are provided compositions and methods for treatment of neurodegeneative diseases and CNS injury. The compositions a pharmaceutically acceptable carrier solution; and a plurality of biodegradable nanoparticles, wherein the nanoparti...  
WO/2014/029732
The present invention relates to the use of novel pyrrolo[2,3- b]]pyrazines wherein all variable substituents are defined as described herein, which are SYK inhibitors and are useful for the treatment of auto-immune and inflammatory dise...  
WO/2014/031656
Disclosed is an antibody which binds to olanzapine, which can be used to detect olanzapine in a sample such as in a competitive immunoassay method. The antibody can be used in a lateral flow assay device for point-of-care detection of ol...  
WO/2014/031403
A method of treating an animal suffering from a painful condition or disease comprising administering to the animal an effective amount of a compound of Formula (I) or pharmaceutically acceptable salt thereof, wherein, the animal is live...  
WO/2014/031844
Methods of reducing undesirable side effects during therapeutic treatment using monomethyl fumarate and prodrugs of monomethyl fumarate are disclosed.  
WO/2014/031901
Methods of treating a disease in a patient comprising administering to a patient in need of such treatment a therapeutically effective amount of a compound selected from: (i) monomethyl fumarate, (ii) a prodrug of monomethyl fumarate, an...  
WO/2014/031694
The disclosure provides antibodies that bind the N-terminal region of tau and also bind to pathological tau aggregates, conformational epitopes and peptides mimicking these epitopes (mimotopes). The antibodies may be used to treat tauopa...  
WO/2014/031894
Improved oral dosage forms of methyl hydrogen fumarate and prodrugs thereof are disclosed. Methods of treating diseases such as multiple sclerosis and psoriasis using such dosage forms are also disclosed.  
WO/2014/029285
The present invention provides the use of cordycepin or derivatives thereof in manufacture of medicaments for anti-depression, said derivatives mean pharmaceutically acceptable salts, esters of crodycepin or glycosides formed by cordycep...  
WO/2014/031600
The invention relates to compounds of Formula I, wherein R1, R2, and R3 are defined in the specification, useful for the synthesis of novel conjugates and immunogens derived from quetiapine. The invention also relates to conjugates of a ...  
WO/2014/031694
The disclosure provides antibodies that bind the N-terminal region of tau and also bind to pathological tau aggregates, conformational epitopes and peptides mimicking these epitopes (mimotopes). The antibodies may be used to treat tauopa...  
WO/2014/031897
Oral dosage forms and granulations with a high loading of (N,N- Diethylcarbamoyl)methyl methyl (2E)but-2-ene-l,4-dioate are disclosed.  
WO/2014/031892
Improved oral dosage forms of methyl hydrogen fumarate and prodrugs thereof are disclosed. Methods of treating diseases such as multiple sclerosis and psoriasis using such dosage forms are also disclosed.  
WO/2014/031975
A method for treating, ameliorating or preventing the onset of anxiety in a subject comprises administering to such subject an NMDA receptor antagonist in an amount that is sub- anesthetic and hypo-analgetic. The NMDA receptor antagonist...  
WO/2014/030128
The invention relates to compound of the formula (I) or a salt thereof, wherein the substituents are as defined in the specification; to its preparation, to its use as medicament and to medicaments comprising it.  
WO/2014/029102
The present invention relates to a thiazine amide derivative and a pharmaceutical use thereof, and particularly to a compound of formula I (in the formula, variables are as described in the specification), a pharmaceutically acceptable s...  
WO/2014/026330
The present invention relates to compounds according to Formula (I) or a pharmaceutically acceptable salt or solvate thereof. Such compounds can be used in the treatment of RORgammaT-mediated diseases or conditions.  
WO/2014/028829
The invention provides novel ligands of Kappa (κ) opioid receptors, such as can be used to modulate a Kappa opioid receptor. Methods of synthesis and methods of use are also provided. Compounds of the invention can be used therapeutical...  
WO/2014/026880
The present invention relates to ethynyl derivatives of formula I wherein R1 is hydrogen or halogen; R2 is C1-3-alkyl or -(CH2)m-O-CH3; n is 2 or 3; m is 1 or 2; or to a pharmaceutically acceptable acid addition salt, to a racemic mixtur...  
WO/2014/028587
The present disclosure relates to nanosized chitosan-statin conjugates, nanosized chitosan-chemotherapeutic agent conjugates, compositions comprising such nanosized chitosan-drug conjugates, and methods of making and using the same. The ...  
WO/2014/028883
The present invention is directed to novel treatment of controlling hippocampal neural circuit hyperexcitability occurring in a neurological disease or disorder associated with epileptogenesis in a subject in need of such treatment, comp...  
WO/2014/026341
Disclosed is an oral drug or health food which main components comprise ginsenoside (Rg1+Rb1+Re), glycyrrhetic acid and chinese date cAMP for increasing content and availability of cAMP in vivo rapidly.  
WO/2014/028800
Disclosed are compounds, compositions and methods for treating various diseases, syndromes, conditions and disorders, including pain. Such compounds are represented by Formula (I) as follows: wherein R1, R2, ring A, and G are defined her...  
WO/2014/026557
The present invention provides a use of 3-amino-1-propanesulfonic acid and derivatives thereof in manufacture of medicaments for the treatment of cardiovascular and cerebrovascular diseases or neurodegenerative diseases. 3-amino-1-propan...  
WO/2014/027885
This invention pertains to the use of an uridine source, preferably uridine monophosphate,for increasing, controlling and/or maintaining fasting plasma uridine concentrations in a range of 4 to 8μM in a subject in need thereof, comprisi...  
WO/2014/028387
Disclosed herein is use of one or more aminopyridines in methods and compositions for improving walking capacity in patients with multiple sclerosis.  
WO/2014/027668
[Problem] To identify an enzyme that decomposes active reelin into an inactive form and to provide an effective treatment and research means for diseases such as Alzheimer's disease based on active reelin decrease using this enzyme and/o...  
WO/2014/027023
The present invention is directed to compositions, preferably dietetic compositions suitable for the treatment of malnutrition, in the treatment of neurological diseases, particularly epilepsy and related diseases such as difficult-to-co...  
WO/2014/027882
This invention pertains to the use of an uridine source, preferably uridine monophosphate,for increasing, controlling and/or maintaining fasting plasma uridine concentrations in a range of 4 to 8 µM in a subject in need thereof, compris...  
WO/2014/028479
The present invention provides compounds of Formula (I) that are GPR6 modulators and are therefore useful for the treatment of diseases treatable by modulation of GPR6, in particular treating Parkinson disease, levodopa induced dyskinesi...  
WO/2014/028868
This application provides a method of preferentially inhibiting monoamine oxidase A (MAOA) in the brain of a subject relative to in the intestine of the subject comprising parenterally administering to the subject a controlled release fo...  
WO/2014/028399
This invention provides a method of treating a human subject suffering from a CB1 receptor related disorder comprising periodically administering to the subject an effective amount of laquinimod or pharmaceutically acceptable salt thereo...  
WO/2014/026881
The invention relates to imidazo[2,1-b]thiazol-3-one derivatives of formula (I) wherein the variables are as defined in the claims. It has been shown that the present compounds may be used for binding and imaging tau aggregates and relat...  
WO/2014/026372
Disclosed is a pharmaceutical composition for inhibiting autophagy of motor neurons containing an effective amount of an active ingredient. The active ingredient is selected from the following groups: a compound of formula (I), pharmaceu...  
WO/2014/024984
The purpose of the present invention is to provide a hydrogen mixed gas supply device capable of administering a mixed gas having the hydrogen gas concentration and the oxygen gas concentration thereof each appropriately adjusted in acco...  
WO/2014/026121
A pharmaceutical composition comprising an amphiphilic emulsifier, a polar liquid carrier and, optionally, a lipid component. The amphiphilic emulsifier form free-moving, optionally lipid-carrying, micelles (LMs) in the polar liquid carr...  
WO/2014/023390
Compounds of the formula (I), in which R1, X, Y and n have the meanings indicated in Claim 1, are inhibitors of Tankyrase, and can be employed, inter alia, for the treatment of diseases such as cancer, cardiovascular diseases, central ne...  
WO/2014/024125
Pyrazolo[4,3-d]pyrimidin-7(6H)-one derivatives represented by the general formula (I), wherein R1 represents hydrogen atom or methyl; when R1 represents hydrogen atom, then R2 represents cyclopentyl, tetrahydropyranyl, cyclohexyl, or cyc...  
WO/2014/025837
Compositions and methods of treatment of tauopathies are provided. In some embodiments, an antagonist of endothelin receptor A (ETA) and endothelin receptor B (ETB) may be administered to a subject to reduce tau production or accumulatio...  
WO/2014/025761
The present invention is based on the discovery that motor neurons derived from patients with a neurodegenerative disease have decreased delayed rectifier potassium current and increased persistent sodium current compared to motor neuron...  
WO/2014/023129
Provided are a new α-conotoxin peptide, and a medical composition and a purpose thereof. Further provided are a propeptide, a nucleic acid construct, an expression vector, a transformed cell and a fusion protein of the conotoxin peptide...  
WO/2014/025808
Provided herein are curcumin analogues that are able to interact with amyloid β (Aβ) and to attenuate the copper-induced crosslinking of Aβ. Also provided herein are methods of using the compounds in the treatment of Alzheimer's Disea...  
WO/2014/025679
The present invention is directed to a process for the preparation of heterocyclic derivatives of formula I (I), wherein J, X, Z, W and R2 are as defined herein using a palladium catalysed aminocarbonylation reaction. Such compounds are ...  
WO/2014/025993
D-amino acid oxidase (DAAO) inhibitors and methods of their use, either alone or in combination with D-serine or D-alanine, to facilitate allosteric activation of NMDA receptor-mediated neurotransmission and methods of their use as thera...  
WO/2014/022879
The present invention relates to compounds for the treatment of mTOR (mammalian Target Of Rapamycin) pathway related diseases. Specifically, the present invention relates to the use of aminoactonitrile derivatives (AADs) in the treatment...  
WO/2014/025019
Provided is a means for improving breeding performance of industrial animals. This animal feed is provided to industrial animals to raise the industrial animals, and is characterized by containing L-valine and L-lysine, and having a mass...  

Matches 451 - 500 out of 46,052